Danish Pharmacovigilance Update, 16 August 2012

In this issue of Danish Pharmacovigilance Update:

• Maximum single dose of intravenous ondansetron (Zofran® and others) now restricted to 16 mg (front page)
• Correlation between calcitonin and malignant disease – new restrictions on the use and withdrawal of nasal spray from the market (p 2)
• Risk of impulse control disorders in patients undergoing treatment with dopamine-increasing drugs (p 2)
• Serious skin reactions correlated to the use of carbamazepine, oxcarbazepine or allopurinol and association with certain genetic alleles (p 3)
• Reports of suicide correlated to initiation of antidepressants (p 4)
• Medication errors and incorrect use of Exelon® transdermal patch for treatment of Alzheimer’s dementia (p 5)
• Short news (pp 5-6)
• Medicintjek (Medicine check): Mobile app with information about medicines (p 7)